1st Faculty of Medicine Charles University 1st Faculty of Medicine Charles University Genes, Genetics & Genomics

2017 - 2018 G3 series

First Faculty of Medicine Charles University (1.LF UK), Biotechnology and biomedicine Centre of the Academy of Science andCharles University (BIOCEV) andInstitute of Hematology and Blood Transfusion (UHKT)

                                                                                           invite you to

international Symposium G3 (Genes, Genomics, Genetics)devoted to recent discoveries in Hematology of myelogenous Diseases.

                                            MARCH 16, 2018 9.00 A.M. – 2.00 P.M. Dean's Office (Na bojišti 3, Praha 1)


The cessation of tyrosine kinase inhibitor treatment in a proportion of patients with chronic myeloid leukemia and deep molecular response will be soon applied in clinical practice because the biggest pan European clinical trial EURO-SKI (The European Stop Kinase Inhibitor) has finished and data will be published soon. Definition of important preconditions for sustained treatment free remission (TFR) is critical for guidance for treatment stopping criteria. Apart of two criteria, duration of deep molecular response and pre-stopping TKI therapy duration, an immunological status much importantly prerequisite for cessation of TKI therapy.

This symposium is focused on the immunological aspects of CML patients and their response to treatment. Andreas Burchert and Satu Mustjoki are principal investigators of systematic analysis of immune response parameters to predict response to TKI and sustained deep molecular response after TKI cessation. Ingo Roeder is applying math to create models for prediction sustained TFR without treatment.


Professor Satu Mustjoki, MD, PhD

University of Helsinki (Medicum) & Helsinki University Hospital

Professor Andreas Burchert, MD

Universitätsklinikum Gießen und Marburg

Professor Ingo Roeder, PhD

Carl Gustav Carus Faculty of Medicine, Dresden

G3 Workshop dedicated to small "Non-coding RNA in Hematologic Malignancies" is scheduled to be held in Biocev for November 16, 2017 starting at 2 p.m.

Open session:

2.00-2.30 P.M.

Dr. Tomáš Stopka (BIOCEV First Medical Faculty Charles University and General Faculty Hospital): MiRNA as a biomarker in hematooncology and solid oncology.

2.30-3 P.M.

Dr. Pavel Burda (Institute of Haematology and Blood Transfusion): Targets of microRNA in Chronic myeloid leukemia.

Closed session 3.00-4.00 P.M.:

Dr. Petr Cigler (Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences): collaborative projects, proposals



Organizers: Tomas Stopka & Katerina Machova-Polakova


1st Faculty of Medicine, Charles University & Institute of Haematology and Blood Transfusion (ÚHKT)